Incannex announces additional appointments to Clinical Advisory Board

Incannex (IXHL) Healthcare announced the appointment of three additional members to its recently established Clinical Advisory Board: Murray Stein, MD, MPH; Andrew Cutler, MD; and Amir Kalali, MD. The CAB was formed to provide independent clinical and scientific guidance as the Company progresses PSX-001 into its next phase of clinical and regulatory development. Among its roles, the CAB will advise Incannex on clinical trial design, endpoint selection, regulatory engagement, and broader development strategy as PSX-001 advances.